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Abstract
Background: Linkage and congenic strain analyses using the nonobese diabetic (NOD) mouse as a model for human
type 1 autoimmune diabetes (T1D) have identified several NOD mouse Idd (insulin dependent diabetes) loci, including
Slc11a1 (formerly known as Nramp1). Genetic variants in the orthologous region encompassing SLC11A1 in human
chromosome 2q35 have been reported to be associated with various immune-related diseases including T1D. Here, we
have conducted association analysis of this candidate gene region, and then investigated potential correlations
between the most T1D-associated variant and RNA expression of the SLC11A1 gene and its splice isoform.
Methods: Nine SNPs (rs2276631, rs2279015, rs1809231, rs1059823, rs17235409 (D543N), rs17235416 (3’UTR), rs3731865
(INT4), rs7573065 (-237 C®T) and rs4674297) were genotyped using TaqMan genotyping assays and the polymorphic
promoter microsatellite (GT)n was genotyped using PCR and fragment length analysis. A maximum of 8,863 T1D British
cases and 10,841 British controls, all of white European descent, were used to test association using logistic regression.
A maximum of 5,696 T1D families were also tested for association using the transmission/disequilibrium test (TDT). We
considered P ≤ 0.005 as evidence of association given that we tested nine variants in total. Upon identification of the
most T1D-associated variant, we investigated the correlation between its genotype and SLC11A1 expression overall or
with splice isoform ratio using 42 PAXgene whole blood samples from healthy donors by quantitative PCR (qPCR).
Results: Using the case-control collection, rs3731865 (INT4) was identified to be the variant most associated with
T1D (P = 1.55 × 10-6). There was also some evidence of association at rs4674297 (P = 1.57 × 10-4). No evidence of
disease association was obtained at any of the loci using the family collections (PTDT ≥ 0.13). We also did not
observe a correlation between rs3731865 genotypes and SLC11A1 expression overall or with splice isoform
expression.
Conclusion: We conclude that rs3731685 (INT4) in the SLC11A1 gene may be associated with T1D susceptibility in
the European ancestry population studied. We did not observe a difference in SLC11A1 expression at the RNA level
based on the genotypes of rs3731865 in whole blood samples. However, a potential correlation cannot be ruled
out in purified cell subsets especially monocytes or macrophages.
Background
Type 1 diabetes (T1D) is a heritable polygenic autoim-
mune disease in which both genetic and environmental
factors contribute to pathogenesis. To date over 50 loci
have been identified that affect risk of T1D [1-3]. The
causal genes, variants and haplotypes involved within
many of these regions have yet to be identified.
The nonobese diabetic (NOD) mouse develops autoim-
mune insulin-dependent diabetes spontaneously, which
resembles human T1D, and has been widely used to study
and map non-MHC T1D loci. The loci identified in the
NOD mouse as high priority candidates for human T1D
studies include solute carrier family 11 member 1
(Slc11a1), which was formerly known as natural resis-
tance-associated macrophage protein 1 (Nramp1) [4].
Slc11a1 is encoded in the Idd5.2 region on mouse chro-
mosome 1. The NOD strain with the disease-predisposing
allele expresses the functional protein, whereas the T1D-
resistant B10 strain does not [5,6]. The NOD allele was
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originally identified as providing resistance to bacterial
infections in mice. Kissler et al. used RNA interference to
reduce Slc11a1 expression in vivo in NOD mice, and
found that this reduced the frequency of T1D, mimicking
the protective Idd5.2 T1D-resistant haplotype [7]. Further-
more, Slc11a1 was found to augment activation of a diabe-
togenic T-cell clone by enhancing the processing and
presentation of pancreatic islet antigens, such as glutamic
acid decarboxylase GAD65, in dendritic cells (DCs) [8].
In humans, SLC11A1 is 14 kb in length with 15 exons.
The gene is located in an approximately 400 kb region of
high linkage disequilibrium (LD) on chromosome 2q35.
The human and mouse SLC11A1 protein sequences have
a high degree of conservation, with 88% identity and 93%
overall sequence similarity [9]. SLC11A1 is expressed in
monocytes [10,11], which are the circulating precursors
of macrophages and DCs, the major antigen-presenting
cells in the immune system. SLC11A1 has pleiotropic
effects on macrophage function, all of which are impor-
tant in resistance to intracellular pathogens. These
include release of nitric oxide, L-arginine flux, oxidative
burst, tumouricidal and antimicrobial activities, as well as
upregulation of CXC chemokine KC, tumour necrosis
factor-a, interleukin-1b, inducible nitric oxide synthase
and MHC class II expression [12,13]. Roles of monocytes
and macrophages have been implicated in the pathogen-
esis of T1D [14,15]. Recently, macrophages have been
shown to be one of the major immune cell populations
in infiltrated pancreatic islets of autopsy tissues from
patients with T1D [15,16], suggesting that macrophages
may contribute to the early phase of beta-cell destruction.
Together with the evidence showing that over-activation
of SLC11A1 could potentially induce and maintain auto-
immune diseases, these data make SLC11A1 a candidate
gene for autoimmune and immune-mediated disorders,
such as T1D. Interestingly, SLC11A1 has been shown to
suppress IL-10 production [17], and the gene that
encodes IL-10 has recently been associated with T1D
susceptibility [1,18], as well as with risk of ulcerative coli-
tis [19] and of systemic lupus erythematosus [20].
Genetic variants in the SLC11A1 gene region have been
reported to be associated with various infectious [21-29]
and chronic immune diseases, such as T1D [30-33], rheu-
matoid arthritis (RA) [34-37], juvenile RA (also known as
juvenile idiopathic arthritis; JIA) [38,39], sarcoidosis [40],
inflammatory bowel disease (IBD) [41-45], Kawasaki dis-
ease [46] and multiple sclerosis [47]. More recently,
SLC11A1 has also been claimed to be associated with Beh-
cet’s syndrome in a Turkish population [48] and esopha-
geal cancer in a South African population [49]. Blackwell
et al. identified a potentially functional polymorphic
microsatellite with Z-DNA forming dinucleotide repeats
in the promoter region of the human SLC11A1 gene
[50,51]. Allele 3 with the apparent stronger promoter
activity that drives higher expression of SLC11A1 relative
to allele 2 may result in chronic macrophage hyperactiva-
tion, thus predisposing to autoimmune diseases, but pro-
tecting against infectious diseases (see additional file 1 for
microsatellite allele sequences) [51]. However, not all stu-
dies have replicated the association of the promoter poly-
morphism in T1D [31,32]. Indeed, associations at other
polymorphisms, such as rs17235409 (D543N), rs17235416
(3’UTR) and rs3731865 (INT4), have been reported in
immune-related and infectious diseases [22,23,25-28,
35-37,39,43], implying that alternative variants may be
causal. In IBD, Zaahl et al. have shown that the SLC11A1
association involves a protective effect of the promoter
SNP, rs7573065 (-237 C®T) [44]. They previously found
that in the presence of allele 3 of the 5’ microsatellite, the
change from allele C to T at rs7573065 (-237 C®T) low-
ered the expression of SLC11A1, to a similar level as
observed with allele 2 of the microsatellite [52]. Combined,
these data suggest that both rs7573065 (-237 C®T) and
the microsatellite (r2 = 0.02 and D’ = 0.98 in controls; see
additional file 2) together might be associated with disease.
Previously, Maier et al. found no evidence of association
of SLC11A1 with T1D using four tag SNPs (rs2276631,
rs2279015, rs1059823 and rs1809231), but only 1,709 T1D
cases, 1,829 controls and 1,632 families were studied [4].
They also genotyped the non-synonymous SNP (nsSNP)
rs17235409 (D543N) and the microsatellite (GT)n in 1,632
families and did not obtain any evidence of association [4].
Nor did they obtain evidence of association with the
nsSNP rs17235409 (D543N), which was genotyped in an
additional 1,995 cases and 2,101 controls [4]. The gen-
ome-wide association study (GWAS) performed by the
Wellcome Trust Case Control Consortium (WTCCC)
identified a SNP, rs4674297, in MGC50811 (also known as
C2orf62), located within the same LD block as SLC11A1
that showed some evidence of association with T1D (P =
0.0070) [53]. Barrett and colleagues performed a meta-
analysis of three GWAS totalling 7,514 cases and 9,045
controls [1]. They found rs4674297 was one of the four
most T1D-associated SNPs in the region with P-values of
around 10-4 [1]. Following the additional functional sup-
port obtained using the NOD mouse model [7,8], we have
performed a comprehensive association analysis of
sequence polymorphisms in the SLC11A1 region in a max-
imum of 8,863 unrelated T1D cases and 10,841 controls as
well as up to 5,696 T1D families in order to identify the
most associated, potentially causal, T1D variant(s) and its
effect on expression and splicing of the SLC11A1 gene.
Results and discussion
We genotyped and analysed three of the Maier et al. tag
SNPs (rs2276631, rs2279015 and rs1809231 [4]), the
nsSNP rs17235409 (D543N), the indel rs17235416
(3’UTR), rs3731865 (INT4), rs7573065 (-237 C®T) and
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rs4674297 in up to 5,878 cases and 6,406 controls
(Figure 1 and Table 1). As the promoter microsatellite
(GT)n has been suggested to be a functional variant, we
genotyped this polymorphism in the maximum number of
samples in the collection available at the time, which was
7,894 cases and 7,560 controls (Figure 1 and Table 1).
Since rs3731865 (INT4), the indel rs17235416 (3’UTR)
and rs4674297 showed the most evidence of association
with T1D (P ≤ 0.005; Figure 1), they were genotyped in
our extended case-control collection in an additional
2,985 cases and 4,435 controls to test whether their effects
were independent.
We had over 96% power to detect an effect size of 0.90,
at an alpha level of 0.005, assuming a multiplicative allelic
effects model and a minor allele frequency (MAF) of 0.29,
with a sample size of 8,863 cases and 10,841 controls.
rs3731865 (INT4) showed the most evidence of associa-
tion with T1D (P = 1.55 × 10-6; OR = 0.90 (95% confi-
dence interval (C.I.) 0.86-0.94); Table 1). The support for
association with T1D at rs4674297, a SNP identified
from the Barrett et al. meta-analysis study (P = 2.9 × 10-
4) [1], was maintained (P = 1.57 × 10-4; OR = 0.91 (95%
C.I. 0.86-0.96); Table 1; 5,897 cases and 5,461 controls in
our full dataset of 8,863 cases and 10,841 controls
overlapped with 7,514 cases and 9,045 controls in the
Barrett et al. meta-analysis study). Our samples were not
genotyped at the other three SNPs, rs12471773,
rs2290708 and rs3816560, found in the meta-analysis as
they are in high LD with the associated SNPs (rs3731865
and rs4674297; r2 > 0.8 in controls) and so are unlikely to
significantly improve the T1D association signal in this
region. We found no evidence of associations that were
independent of rs3731865 (INT4) (P > 0.007).
We obtained no evidence of association with T1D at
any of the nine SLC11A1 polymorphisms genotyped
with T1D in up to 5,696 families (P ≥ 0.13; Table 2).
For the most T1D-associated SNP, rs3731865 (INT4),
the TDT result indicated no association (RR = 1.00
(0.95-1.06), P = 0.98; Table 2) despite being genotyped
in the largest number of families. This could have been
due to a modest level of power (53%) in the family col-
lections to detect an effect size of RR = 0.90 with MAF
of 0.26 at an alpha level of 0.005, assuming a multiplica-
tive allelic effects model. This study had 82% power at
an alpha level of 0.05.
The 2004 IBD study by Zaahl et al. suggested that the
promoter SNP, rs7573065 (-237 C®T), and the micro-
satellite (GT)n might, in combination, be associated
Figure 1 A schematic of the SLC11A1 gene region with the T1D genetic association results using a maximum of 5,878 cases and
6,406 controls for the SNPs and 7,700 cases and 7,380 controls for the microsatellite (GT)n. SNPs with P ≤ 0.005 (horizontal dashed line)
were chosen to be genotyped in our extended case-control collection (maximum of 8,863 T1D cases and 10,841 controls) and are shown in red.
The microsatellite (GT)n is depicted in green. The multiplicative allelic effects model was an appropriate model for all variants (P > 0.05), except
for rs1809231 C > G as there was a significant difference between the genotype and the multiplicative allelic effects models (P = 0.019; Table 1).
[NCBI build 37 was used]
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Table 1 Summary of T1D association results for the case-control collection
Allele or genotype
frequency N (%)
Variant
[Synonym]
Location
Number of
cases
Number of
controls
Allele or
genotype
in cases in controls OR (95% C.I.) P-value
rs4674297 G > A 8502 10071 A 3710 (21.82) 4682 (23.25) 0.91 (0.86-0.96) 1.57 × 10-4
5’ of SLC11A1
within MGC50811 (aka C2orf62) G/G 5210 (61.28) 5945 (59.03) 1.00 (reference)
G/A 2874 (33.80) 3570 (35.45) 0.91 (0.86-0.97)
PHWE = 0.050 A/A 418 (4.92) 556 (5.52) 0.84 (0.74-0.96)
Microsatellite (GT)n 3 > 2 7697 7371 2 3999 (25.98) 4010 (27.20) 0.94 (0.89-0.99) 0.016
Promoter
3*/3* 4195 (54.50) 3913 (53.09) 1.00 (reference)
3*/2 3005 (39.04) 2906 (39.42) 0.96 (0.89-1.03)
PHWE = 0.697 2/2 497 (6.46) 552 (7.49) 0.85 (0.74-0.97)
rs7573065 C > T 5649 6233 T 647 (5.73) 732 (5.87) 0.97 (0.87-1.09) 0.662
[-237 C->T]
Promoter C/C 5018 (88.83) 5518 (88.53) 1.00 (reference)
C/T 615 (10.89) 698 (11.20) 0.97 (0.86-1.09)
PHWE = 0.303 T/T 16 (0.28) 17 (0.27) 1.00 (0.50-2.00)
rs2276631 C > T 5578 6048 T 2933 (26.29) 3331 (27.54) 0.93 (0.87-0.99) 0.016
[274 [C/T]]
Exon 3 C/C 2998 (53.75) 3153 (52.13) 1.00 (reference)
C/T 2227 (39.92) 2459 (40.66) 0.94 (0.87-1.02)
PHWE = 0.144 T/T 353 (6.33) 436 (7.21) 0.84 (0.72-0.98)
rs3731865 G > C 8787 10611 C 4691 (26.69) 6116 (28.82) 0.90 (0.86-0.94) 1.55 × 10-6
[469 +14 [G/C]; INT4]
Intron 4 G/G 4713 (53.64) 5401 (50.90) 1.00 (reference)
G/C 3457 (39.34) 4304 (40.56) 0.91 (0.86-0.97)
PHWE = 0.242 C/C 617 (7.02) 906 (8.54) 0.78 (0.69-0.87)
rs2279015 G > A 5549 5872 A 4312 (38.85) 4658 (39.66) 0.96 (0.91-1.02) 0.205
[1465-85 [A/G]]
Intron 13 G/G 2060 (37.12) 2142 (36.48) 1.00 (reference)
G/A 2666 (48.04) 2802 (47.72) 1.00 (0.92-1.08)
PHWE = 0.817 A/A 823 (14.83) 928 (15.80) 0.92 (0.82-1.03)
rs17235409 G > A 5498 6062 A 241 (2.19) 216 (1.78) 1.28 (1.06-1.55) 0.010
[D543N]
Exon 15 G/G 5259 (95.65) 5849 (96.49) 1.00 (reference)
G/A 237 (4.31) 210 (3.46) 1.31 (1.08-1.59)
PHWE = 0.430 A/A 2 (0.04) 3 (0.05) 0.72 (0.12-4.37)
rs17235416 TGTG> del 8463 9835 del 312 (1.84) 299 (1.52) 1.22 (1.04-1.44) 0.015
[1729+55del4 [TGTG]; 3’UTR]
3’UTR TGTG/TGTG 8153 (96.34) 9539 (96.99) 1.00 (reference)
TGTG/del 308 (3.64) 293 (2.98) 1.24 (1.05-1.46)
PHWE = 0.624 del/del 2 (0.02) 3 (0.03) 0.69 (0.11-4.20)
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with disease [52]. However, these variants are not asso-
ciated with T1D, either together in a joint effects model
(P = 0.33) or individually (P > 0.01; Table 1). We also
assessed whether rs7573065 (-237 C®T) and the micro-
satellite were involved with T1D susceptibility in a hap-
lotypic manner. Haplotype 3.T (microsatellite.rs7573065)
was grouped with all the other haplotypes consisting of
the protective allele 2 of the microsatellite, since they
were found to exert similar effects on transcriptional
activity [52]. Using the most ‘susceptible haplotype’, 3.C,
as the reference, the grouped haplotypes did not show
an association with T1D (P = 0.15; OR = 0.96 (95% C.I.
0.90-1.02)). Furthermore, haplotype 3.T by itself did not
confer protection against T1D (P = 0.32; OR = 0.94
(95% C.I. 0.83-1.07)). Together these analyses suggest
that rs7573065 (-237 C®T) does not confer protection
against T1D, either by itself or in combination with
allele 3 of the microsatellite.
SLC11A1 has several known alternative splice transcripts
of which the two major isoforms expressed are full length
transcripts with or without exon 4a (74 bp in length). Pre-
vious studies have shown that exon 4a, which is located
between exon 4 and 5, encoded by an Alu element, is tran-
scribed in vivo but would introduce two termination
codons in exon 5 resulting in severely truncated, and thus
non-functional, SLC11A1 protein [9]. Interestingly, the
most T1D-associated SLC11A1 polymorphism, rs3731865,
is located in intron 4, 13 bp 3’ of exon 4 and 167 bp 5’ of
the alternatively spliced exon 4a. Although bioinformatics
analyses failed to predict known splice elements around or
at rs3731865, due to its location within the gene, we
hypothesised that rs3731865 might affect elements for
transcription or splicing of SLC11A1 exons. This splicing
could cause changes in functional message levels and the
amount of functional SLC11A1 protein expressed. There-
fore, measuring the ratio of transcripts with or without
exon 4a in the cell population of interest and correlating
the expression of SLC11A1 with genotypes of rs3731865
could be informative for determining the effect of this
SNP on gene expression.
Table 1 Summary of T1D association results for the case-control collection (Continued)
rs1059823 A > G 5,605 6,137 ND ND ND ND ND
[1801+86[A/G]]
3’UTR
PHWE = 0.001
rs1809231 C > G 5643 6151 G 4870 (43.15) 5399 (43.89) 0.97 (0.92-1.02) 0.028**
3’ intergenic region
C/C 1783 (31.60) 1959 (31.85) 1.00 (reference)
C/G 2850 (50.51) 2985 (48.53) 1.04 (0.96-1.14)
PHWE = 0.249 G/G 1010 (17.90) 1207 (19.62) 0.91 (0.82-1.01)
Association of alleles and genotypes were tested using single locus logistic regression.
* Rare microsatellite alleles (with frequency <0.1%) were combined with the common allele 3. ** The multiplicative allelic effects model was an appropriate
model for all variants (P > 0.05), except for rs1809231 C>G where a genotype effects model was required (P = 0.019). [PHWE = Hardy- Weinberg equilibrium in
controls; OR = odds ratio; 95% C.I. = 95% confidence intervals; ND = not done.]
Table 2 Summary of T1D association results for the family collections
Variant Number of
families
Number of
informative
transmissions
Minor allele frequency (%)
in affected siblings
Minor allele frequency (%)
in unaffected parents
Relative risk
(95% C.I.)
Family
PTDT
rs4674297 G>A NA NA NA NA NA NA
Microsatellite (GT)n 3*>2 1971 1925 27.02 27.06 1.00 (0.92-1.10) 0.87
rs7573065 C>T 2472 610 5.43 5.30 0.92 (0.78-1.08) 0.29
rs2276631 C>T 2707 2587 27.38 27.15 1.00 (0.93-1.08) 0.98
rs3731865 G>C 5010 4876 26.43 26.42 1.00 (0.95-1.06) 0.98
rs2279015 G>A 2523 2862 36.33 36.26 0.94 (0.88-1.02) 0.13
rs17235409 G>A 1859 198 2.05 2.10 0.92 (0.70-1.22) 0.57
rs17235416 TGTG>del 2450 191 1.61 1.65 0.85 (0.64-1.14) 0.28
rs1059823 A>G 2591 2950 39.79 38.81 1.02 (0.95-1.10) 0.56
rs1809231 C>G 2678 3166 42.71 42.14 1.01 (0.94-1.08) 0.78
Number of families with genotyping data for the variants in the SLC11A1 gene region with the respective number of informative transmissions, the relative risk
and the P-value from the transmission/disequilibrium test (PTDT). [* Rare microsatellite alleles, with frequency <0.1%, were combined with the common allele 3;
95% C.I. = 95% confidence interval; NA = not available]
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SLC11A1 mRNA is expressed specifically in whole
blood, CD14+ monocytes, CD33+ and CD66b (granulo-
cytes) myeloid cells according to the microarray expres-
sion data available from BioGPS and HaemAtlas [10,11].
Since whole blood samples were available in the labora-
tory, we investigated if the genotypes of rs3731865 cor-
related with the overall expression of SLC11A1 and also
with the isoform ratio in whole blood samples collected
in PAXgene RNA tubes from 42 healthy donors
recruited from Cambridge BioResource (CBR) [54]. It
was hypothesised that in donors homozygous for the
T1D susceptibility allele, there would be increased levels
of transcripts without exon 4a, which codes for func-
tional protein, and less of the alternative transcript,
which encodes premature stop codons and, thus, a non-
functional protein. Thereby an overall higher splice iso-
form ratio is expected in individuals homozygous for
the susceptibility allele compared to individuals homozy-
gous for the protective allele. However, no genotype
effect was detected for expression of SLC11A1 overall or
for isoform ratio differences (P = 0.92 and 0.70, respec-
tively; Figure 2).
The failure to detect SLC11A1 expression differences
based on rs3731865 genotypes could be due to various
reasons, such as there is actually no correlation between
its transcriptional splicing and genotypes of rs3731865 in
whole blood, or there is, but the quantitative PCR
(qPCR) assays are not sensitive enough to detect it, or
perhaps the current sample size may not be large enough
to have sufficient power to detect a small difference. It is
also possible that a purified cell subset should be studied
instead of analysing overall expression in whole blood,
such as monocyte-derived macrophages, where the gene
is known to function.
The incidence of T1D is predicted to double in chil-
dren under 5 years by 2020 [55], with the likely cause
being the changing environment. These environmental
changes could impact our association study, with gene-
environment interactions becoming increasingly impor-
tant. Our control cohort is of similar age to the parents
of our cases. This single generational difference could
still reduce our power to find effects in our case-control
study in the presence of gene-environment interactions,
owing to their differences in early life environmental
exposures. However, this does not affect the significance
of the findings obtained. Taking the data collectively, we
identified the strongest allelic association with T1D at
rs3731865 in intron 4 of SLC11A1. This SNP is also
most associated with JIA in Finnish families in the same
direction where the minor allele is also protective for
disease [39]. Although the promoter microsatellite
remains the only variant reported to date for which
there is evidence of a correlation with function in the
SLC11A1 gene region [43,51], alleles 2 and 3 of the
microsatellite are in strong LD with rs3731865 (r2 =
0.79 in controls; see additional file 2). Therefore, any
T1D association detected for the microsatellite might be
tagging the association of rs3731865. The extensive
prior evidence linking SLC11A1 function and expression
with autoimmune, immune-related and infectious dis-
eases in mice and humans, and the confirmed polygenic
model of T1D inheritance of numerous small effects,
suggest that SLC11A1 variation may well have a very
small effect on human T1D risk [56,57].
Figure 2 SLC11A1 expression by rs3731865 genotype. No genotype effect was detected either for (a) overall expression or for (b) the ratio of
both isoforms. [C = minor protective allele and G = major susceptibility allele]
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A search for additional rare variants via next genera-
tion sequencing, as well as results coming from the
1000 Genomes Project [58], could provide further infor-
mation regarding the possibility of an association of
SLC11A1 with T1D. Recently, Zeller et al. and Heinig
et al. performed a large-scale investigation of the tran-
scriptome of circulating monocytes and monocyte-
differentiated macrophages using the Illumina Human
HT-12 expression BeadChips [14,59]. The two microar-
ray probes (ILMN_1741165 and ILMN_1735737) in
SLC11A1 mapped to the 3’UTR of the gene. Using the
data from Heinig et al. a stronger expression signal is
detected by the ILMN_1741165 probe compared to the
other probe [14]. Although expression quantitative trait
loci (eQTL) and eSNPs for SLC11A1 were identified from
these studies for the ILMN_1741165 probe, including the
T1D-associated SNP, rs4674297 (P = 1.03 × 10-65) [59],
this probe maps to repeat sequences [14,59]. Therefore
the eQTL identified for SLC11A1 is highly questionable
and could be an artefact. Only about 39% of eQTLs are
likely to be due to “simple effect” SNPs, those that altered
transcription levels [60]. The majority of eQTL variations
are, however, owed to other alterations in gene expression,
namely altered initiation/termination and/or splicing [60].
Hence, analysis of microarrays with multiple probes per
gene and per exon e.g. Affymetrix Gene Array, and, in the
future, direct RNA sequencing using the next generation
technologies should be more informative. Investigating the
correlation of SLC11A1 RNA expression and protein level
in genotyped human macrophage/stimulated monocyte or
DC samples based on the genotype/haplotype of the most
T1D-associated variant(s) would help to prove causality of
the genes in human T1D and help to identify biological
disease mechanisms involved in pathogenesis of T1D.
Conclusion
We conclude that genetic variation of the SLC11A1
gene could possibly be associated with T1D susceptibil-
ity. We did not observe a difference in SLC11A1 expres-
sion at the RNA level based on the genotypes of the
SNP most associated with T1D, rs3731865 (INT4), in
whole blood samples. However, a potential correlation
cannot be ruled out in purified blood cell subsets.
Methods
Subjects
We genotyped a maximum of 8,863 T1D cases and
10,841 controls of self-reported white ethnicity collected
from across Great Britain, with non-European subjects
excluded by GWAS genotyping results (see Genetic
association statistical analysis). All cases were recruited
as part of the Juvenile Diabetes Research Foundation/
Wellcome Trust Diabetes and Inflammation Laboratory
U.K. Genetic Resource Investigating Diabetes (GRID)
study [61]. All cases were diabetic defined using the
WHO criteria. Most were less than 16 years of age at
the time of collection and all were diagnosed before 17
years of age, with a mean age-at-diagnosis of 7.8 years.
Controls were obtained from the British 1958 Birth
Cohort (n = 7,658 [62]) and the UK Blood Service’s col-
laboration with the WTCCC (n = 3,183 [63]). A collec-
tion of 5,696 families of European ancestry were also
genotyped. These included 470 multiplex families from
the Diabetes UK Warren 1 repository, 263 simplex
families from Northern Ireland, 80 simplex families
from Yorkshire, 734 simplex families from Finland, 360
simplex families from Norway, 423 simplex families
from Romania, 335 multiplex families from the Human
Biological Data Interchange (U.S.) and 3,031 families
made available through the T1DGC [64]. The T1DGC
families comprised of 362 families from the Asia-Pacific
region, 873 families from across Europe, 1,633 from
North America and 163 from the U.K. [65]. All families
had samples from both parents and at least one affected
child. Families exhibiting misinheritances were excluded.
All DNA samples were collected with approval from the
relevant research ethics committees and written
informed consent was obtained from the participants or
their guardians, if they were too young to consent.
PAXgene whole blood samples were obtained from 42
healthy subjects of self-reported white ethnicity with non-
autoimmune disease status from the Cambridge BioRe-
source (CBR) [54] and selected by SLC11A1 genotype.
T1D patients were excluded in this study to avoid any
confounding due to T1D status or to insulin treatment.
Informed consent was obtained from all volunteers upon
recruitment to the CBR for the collection and use of DNA
samples for genotyping. Ethical approval for this study was
given by the Cambridgeshire 3 Research Ethics Committee
and an informed consent was obtained for the collection
and use of the fresh peripheral blood samples.
Genotyping
Nine SNPs (rs2276631, rs2279015, rs1809231, rs1059823,
rs17235409, rs17235416, rs3731865, rs7573065 and
rs4674297) were genotyped using Custom TaqMan®
SNP Genotyping Assays (Applied Biosystems (ABI))
according to manufacturers’ protocols. The microsatellite
(GT)n was amplified using AmpliTaq® (ABI) using 5’
FAM labelled forward primer (5’-6ttcaatgcatgtcccttctg-3’)
and reverse primer (5’-ccatggagtggacctttgtt-3’) in 6 μl
reaction volume with the following PCR conditions: an
initial denaturation at 95°C for 5 minutes, then 25 cycles
of denaturation at 94°C for 30 seconds, annealing at 65°C
for 30 seconds and extension at 72°C for 30 seconds,
with a final extension at 72°C for 10 minutes. 2 μl of PCR
amplified product was added to 10 μl of pre-diluted Gen-
eScan LIZ500 size standard (25 μl of LIZ500 in 1 ml of
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Hi-Di Formamide; ABI) and heated at 95°C for 5 minutes
before being resolved on ABI PRISM 3730XL Genetic
Analyzer (ABI) and scored on GeneMapper v.4.0 soft-
ware (ABI).
Case and control DNA samples were distributed
evenly on 384-well plates for genotyping. All genotyping
data were scored by one researcher and reviewed by a
second to minimise error. Both researchers were una-
ware of case-control status and family structure. 58 out
of 2,275 96-well case-control DNA plates (2.5%) in this
experiment had some scoring differences, 29 in one well
only, and with only one DNA plate (of whole genome-
amplified samples) requiring substantial review. Geno-
typing success rates ranged from 93.3% to 97.5% for the
nine SNPs and the microsatellite (GT)n. Across the full
case-control collection, there were a maximum of 298
duplicates, the majority (262) being control samples that
have been submitted twice. There were no duplicates in
the family collections. Across the nine SNPs and the
microsatellite the overall concordance rates were 99.6%
and 96.9%, respectively. Hardy-Weinberg equilibrium
was calculated on a plate-by-plate basis in addition to
the entire case and control samples to highlight any
erroneous plates. Genotypes of rs1059823 were found to
deviate significantly from Hardy-Weinberg equilibrium
in the controls (P = 0.001) and, therefore, rs1059823
was not tested for association with T1D using the case-
control collection.
Genetic association statistical analysis
All statistical analyses were performed in the statistical
package, STATA v10.0 [66]. There was no difference in
allele frequencies between the two control cohorts [53].
Most of the samples used here have also been part of a
GWAS and as such have been subjected to rigorous
testing for population heterogeneity [1,53]. Any non-
Caucasian and related individuals identified through pre-
vious GWAS have also been removed [1,53,56,67,68].
Association with T1D was tested using logistic regres-
sion models. Cases and controls were matched accord-
ing to 12 broad geographical subregions of England,
Scotland and Wales (Southwestern, Southern, Southeast-
ern, London, Eastern, Wales, Midlands, North Midlands,
Northwestern, East and West Riding, Northern, and
Scotland), based on the place of recruitment and the
place of birth, respectively, to minimise confounding
due to geographical differences in allele frequency and
disease incidence. Each genetic variant was first tested
for association using a multiplicative allelic effects
model on one degree of freedom (df), with counts of the
minor allele, coded 0, 1, 2, as the dependent variable,
disease status as the outcome variable and geographical
subregions included as strata. Each variant was tested
using a genotype effects model (on two df) that did not
assume a specific inheritance model. The genotype and
allelic effects models were compared using a likelihood
ratio test. Except for rs1809231, the multiplicative allelic
effects model was reported as it was not significantly
different from the genotype effects model (P > 0.05).
Although the reported P-values were not adjusted for
multiple testing, the P-value threshold required for sta-
tistical significance was adjusted. We performed nine
independent tests and so only considered an association
significant if P ≤ 0.005. Power calculations for the
genetic association analyses for the case-control dataset
was performed using CaTS as described in Skol et al.
[69], and for the family datasets, using the method
developed by Knapp [70].
Forward logistic regression analyses were performed to
test for associations with T1D that were independent of
the effect of rs3731865, in other words, evidence against
the most significant SNP, rs3731865, being sufficient to
model the association in the SLC11A1 region [71]. Each
variant in turn was added to a model that included
rs3731865, and a likelihood ratio test was used to assess
whether there was an additional independent effect.
To estimate the joint effects of the microsatellite (GT)
n and rs7573065 (-237 C®T SNP), both variants were
included in the logistic regression model, under the
assumption of multiplicative allelic effects.
Haplotype logistic regression analysis was also carried
out for the microsatellite (GT)n and rs7573065 (-237
C®T SNP). Phased haplotypes were generated under
the null hypothesis that case and control haplotypes
were drawn from the same population using the
SNPHAP program, version 1.3.1. 1,000 Expectation
Maximum (EM) iterations were used, each started from
a random imputation, and only using samples genotyped
at both loci. Haplotypes were tested for association in a
logistic regression model, where haplotype assignments
were weighted by their posterior probabilities, and
robust variance estimates were used to account for non-
independence when multiple haplotype assignments
were possible for each subject.
The transmission/disequilibrium test (TDT) was used
to analyse family data for association with disease [72].
SLC11A1 gene expression assays
Whole blood samples from 42 healthy CBR donors were
collected directly into PAXgene Blood RNA tubes (PreA-
nalytiX). RNA was extracted on the day of blood sample
collection using the PAXgene Blood RNA kit (QIAGEN/
BD) with DNase I treatment according to manufacturers’
protocols. 1 μg of total RNA was used for each reverse
transcription (RT) reaction for synthesising cDNA
primed with oligo dT primer (18-mer) using Super-
script™ III (Invitrogen) according to manufacturers’
instructions. To assess whether RNA samples were
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contaminated with genomic DNA, a corresponding RT-
negative control template was set up for each RT reac-
tion. A qPCR assay designed to amplify genomic DNA
was used to detect DNA contamination within the RT-
negative control sample. SLC11A1 qPCR assays were
designed using Primer3Plus software [73] and checked
for specificity using the Basic Local Alignment Search
Tool (BLAST; see additional file 3 for primer and probe
sequences). qPCR reactions were run in MicroAmp™
Optical 384-well plates (ABI) in a total reaction volume
of 20 μl containing 2 μl of cDNA sample, 0.6 μl of 10 μM
forward and reverse primers each, 0.8 μl of 5 μM probe,
10 μl of TaqMan Universal PCR Master Mix (ABI) and
6 μl of dH2O. The thermal cycling conditions started
with 50°C for 2 minutes, initial denaturation at 95°C for
10 minutes, followed by 40-50 cycles of denaturation at
95°C for 15 seconds and annealing/extension at 60°C for
1 minute. Samples were run in duplicates on the same
plate, and fluorescent signals detected using an ABI
7900HT plate reader (ABI) with SDS v2.2.2 software
(ABI). Data was analysed using comparative cycle num-
ber (CT) method, averaged and normalised by the endo-
genous B2M control ran on the same plate. Correlations
between SLC11A1 overall gene expression and splice iso-
form ratio with rs3731865 genotypes were tested using
ANOVA using the GraphPad Prism software.
Additional material
Additional file 1: Sequences of the human SLC11A1 polymorphic
microsatellite and the allele frequencies in controls.
Additional file 2: The pair-wise linkage disequilibrium (as measured
by r2 and D’) between the genotyped variants in the SLC11A1 gene
region using the genotyping data from 10,841 controls.
Additional file 3: Quantitative PCR primer and probe sequences.
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